Skip to main content
. Author manuscript; available in PMC: 2024 Jul 1.
Published in final edited form as: Gynecol Oncol. 2023 May 26;174:262–272. doi: 10.1016/j.ygyno.2023.05.059

Figure 5. Survival outcomes in high-risk histologic types and in copy number-low endometrial cancer patients by chromosomal instability.

Figure 5.

A. Fraction of genome altered (FGA, %) among copy number-high (CN-H) endometrial cancers of serous histology (n=265), endometrioid histology (n=74), and carcinosarcoma (n=195). B. Progression-free survival (PFS) and overall survival (OS) of patients meeting survival criteria with endometrial carcinomas of CN-H serous (n=82), CN-H endometrioid (n=32), and CN-H carcinosarcoma (n=78) histologic types. C. PFS and OS of patients with CN-low (CN-L) endometrial cancer (n=249; survival cohort) dichotomized by the median FGA of CN-H endometrial cancer (median 20%; Supplementary Fig. S4). Survival compared with log-rank test.